CTLA4 and neoplasm: The diversity of TCRαβ repertoire is associated with efficient protection against several pathogens (81), and more recently, the clonality of both peripheral blood and tumor TCRαβ repertoire has also been associated with improved clinical outcome under anti-PD-1 or anti-CTLA-4 immunotherapy (82–84).